Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
June 01 2022 - 4:00PM
Esperion (NASDAQ: ESPR) today announced the appointment of J.
Martin Carroll as Chairperson of Esperion’s Board of Directors. Mr.
Carroll will serve as a Class I director with a term expiring at
the 2023 annual meeting of stockholders.
"On behalf of the Esperion team and our directors, I am excited
to welcome Marty as Chairperson of the Esperion Board. With his
significant experience, Marty will provide additional leadership
and strategic guidance to our Board as we continue to commercialize
our medicines and advance our pipeline,” said Sheldon Koenig,
president and chief executive officer of Esperion. “Marty’s
expertise will be critical as we prepare for the readout of our
landmark CLEAR Outcomes trial in the first quarter of 2023.”
"I am excited to join Esperion at this pivotal time in the
company’s history with the upcoming readout of the CLEAR Outcomes
study topline results, and continued development of their pipeline
programs,” said Mr. Carroll. “I look forward to supporting the
organization in positioning Esperion as a cardiovascular biotech
leader.”
Mr. Carroll served as President and Chief Executive Officer of
Boehringer Ingelheim Corporation and of Boehringer Pharmaceuticals,
Inc. from 2003 until 2011 and as a director of Boehringer Ingelheim
Corporation from 2003 until December 2012. He joined the
organization in 2002 as President of Boehringer Pharmaceuticals,
Inc. Mr. Carroll worked at Merck & Co., Inc. from 1976 to 2001.
From 1972 to 1976, Mr. Carroll served in the United States Air
Force where he attained the rank of Captain. He has served as a
director of Catalent Pharma Solutions since July 2015, and in
October 2021, was elected as Lead Director. Mr. Carroll served as a
director of Inotek Pharmaceuticals Corporation from March 2016
until January 2018, including serving as Chairman of Inotek from
June 2016 until January 2018. In addition, Mr. Carroll has served
on a number of Board of Directors beginning with Accredo Health in
2004.
Esperion TherapeuticsEsperion works hard to
make our medicines easy to get, easy to take and easy to have. We
discover, develop, and commercialize innovative medicines and
combinations to lower cholesterol, especially for patients whose
needs aren’t being met by the status quo. Our entrepreneurial team
of industry leaders is inclusive, passionate and resourceful. We
are singularly focused on managing cholesterol so you can improve
your health easily. Esperion commercializes NEXLETOL® (bempedoic
acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets and is
the leader in the development of convenient oral, once-daily
non-statin LDL-cholesterol lowering drugs for patients with high
levels of bad cholesterol. For more information, please visit
www.esperion.com and follow us on Twitter at
www.twitter.com/EsperionInc.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding marketing strategy and commercialization
plans, future operations, commercial products, clinical
development, plans for potential future product candidates,
financial condition and outlook, and other statements containing
the words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking
statements involve risks and uncertainties that could cause
Esperion’s actual results to differ significantly from those
projected, including, without limitation, the impact of the ongoing
COVID-19 pandemic on our business, revenues, results of operations
and financial condition, the net sales, profitability, and growth
of Esperion’s commercial products, clinical activities and results,
supply chain, commercial development and launch plans, and the
risks detailed in Esperion’s filings with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Esperion
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Contact:Esperion Corporate
Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024